Platelet-derived growth factor-BB protects mesenchymal stem cells (MSCs) derived from immune thrombocytopenia patients against apoptosis and senescence and maintains msc-mediated immunosuppression

Stem Cells Translational Medicine

Volumn 5, Issue 12, 2016, Pages 1631-1643

  Zhang, Jia Min ^a,b,c   Feng, Fei Er ^a   Wang, Qian Ming ^a   Zhu, Xiao Lu ^a   Fu, Hai Xia ^a   Xu, Lan Ping ^a,b,c   Liu, Kai Yan ^a,b,c   Huang, Xiao Jun ^a,b,c   Zhang, Xiao Hui ^a,b,c  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b Beijing Military Area Command of Chinese PLA   (China)

^c PEKING UNIVERSITY   (China)

Author keywords

Apoptosis; Immunosuppression; Mesenchymal stem cells; Platelet derived growth factor BB; Senescence

Indexed keywords

BETA GALACTOSIDASE; BETA TUBULIN; CASPASE 3; CASPASE 8; CASPASE 9; INTERLEUKIN 10; INTERLEUKIN 4; LIPOCORTIN 5; PLATELET DERIVED GROWTH FACTOR BB; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; PUMA PROTEIN; SURVIVIN; ANTIBODY; BECAPLERMIN; DEATH RECEPTOR; FIBRINOGEN RECEPTOR; PLATELET DERIVED GROWTH FACTOR B;

APOPTOSIS; ARTICLE; CELL CYCLE ASSAY; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CELL STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOFLUORESCENCE; IMMUNOREGULATION; MESENCHYMAL STEM CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; SENESCENCE; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; BIOLOGICAL MODEL; CELL AGING; CELL NUCLEUS; CELL PROTECTION; CYTOLOGY; DRUG EFFECTS; IMMUNOSUPPRESSIVE TREATMENT; MESENCHYMAL STROMA CELL; METABOLISM; MITOCHONDRION; PATHOLOGY;

ANTIBODIES; APOPTOSIS; CELL AGING; CELL NUCLEUS; CELL PROLIFERATION; CYTOPROTECTION; HUMANS; IMMUNOSUPPRESSION; MESENCHYMAL STROMAL CELLS; MITOCHONDRIA; MODELS, BIOLOGICAL; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROTO-ONCOGENE PROTEINS C-SIS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTORS, DEATH DOMAIN; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84995899346     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2015-0360     Document Type: Article

References (57)

1. Cines DB, Cuker A, Semple JW. Pathogenesis of immune thrombocytopenia. Presse Med 2014;43:e49–e59.
2. Semple JW, Provan D, Garvey MB et al. Recent progress in understanding the pathogenesis of immune thrombocytopenia. Curr Opin Hematol 2010;17:590–595.
3. Mouzaki A, Theodoropoulou M, Gianakopoulos I et al. Expression patterns of Th1 and Th2 cytokine genes in childhood idiopathic thrombocytopenic purpura (ITP) at presentation and their modulation by intravenous immunoglobulin G (IVIg) treatment: Their role in prognosis. Blood 2002;100:1774– 1779.
4. Liu B, Zhao H, Poon MC et al. Abnormality of CD4(+)CD25(+) regulatory T cells in idiopathic thrombocytopenic purpura. Eur J Haematol 2007;78:139–143.
5. Nishimoto T, Kuwana M. CD4+CD25 +Foxp3+ regulatory T cells in the pathophysiology of immune thrombocytopenia. Semin Hematol 2013;50(suppl 1):S43–S49.
6. Kim N, Im KI, Lim JY et al. Mesenchymal stem cells for the treatment and prevention of graft-versus-host disease: Experiments and practice. Ann Hematol 2013;92:1295–1308.
7. Almeida-Porada G, Porada CD, Tran N et al. Cotransplantation of human stromal cell progenitors into preimmune fetal sheep results in early appearance of human donor cells in circulation and boosts cell levels in bone marrow at later time points after transplantation. Blood 2000;95:3620–3627.
8. English K, Ryan JM, Tobin L et al. Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. Clin Exp Immunol 2009; 156:149–160.
9. Glennie S, Soeiro I, Dyson PJ et al. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005;105:2821–2827.
10. Tabera S, Pérez-Simón JA, Díez-Campelo M et al. The effectof mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes. Haematologica 2008;93:1301– 1309.
11. Beyth S, Borovsky Z, Mevorach D et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 2005;105:2214–2219.
12. Tasso R, Ilengo C, Quarto R et al. Mesenchymal stem cells induce functionally active T-regulatory lymphocytes in a paracrine fashion and ameliorate experimental autoimmune uveitis. Invest Ophthalmol Vis Sci 2012; 53:786–793.
13. Li X, Liu L, Meng D et al. Enhanced apoptosis and senescence of bone-marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus. Stem Cells Dev 2012;21:2387–2394.
14. Mohanty ST, Kottam L, Gambardella A et al. Alterations in the self-renewal and differentiation ability of bone marrow mesenchymal stem cells in a mouse model of rheumatoid arthritis. Arthritis Res Ther 2010;12:R149.
15. Bacigalupo A, Valle M, Podestà M et al. T-cell suppression mediated by mesenchymal stem cells is deficient in patients with severe aplastic anemia. Exp Hematol 2005;33: 819–827.
16. Pérez-Simón JA, Tabera S, Sarasquete ME et al. Mesenchymal stem cells are functionally abnormal in patients with immune thrombocytopenic purpura. Cytotherapy 2009;11:698–705.
17. Zhang D, Li H, Ma L et al. The defective bone marrow-derived mesenchymal stem cells in patients with chronic immune thrombocytopenia. Autoimmunity 2014;47:519–529.
18. Heldin CH. Autocrine PDGF stimulation in malignancies. Ups J Med Sci 2012;117: 83–91.
19. Vantler M, Karikkineth BC, Naito H et al. PDGF-BB protects cardiomyocytes from apoptosis and improves contractile function of engineered heart tissue. J Mol Cell Cardiol 2010;48:1316–1323.
20. Cabezas R, Avila MF, Gonzalez J et al. PDGF-BB protects mitochondria from rotenone in T98G cells. Neurotox Res 2015;27:355–367.
21. Provan D, Stasi R, Newland AC et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115:168–186.
22. Dominici M, Le Blanc K, Mueller I et al. Minimal criteria for defining multipotent mesenchymal stromal cells: The International Society for Cellular Therapy position statement. Cytotherapy 2006;8:315–317.
23. Sato K, Ozaki K, Oh I et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007;109:228–234.
24. Kuwana M, Kaburaki J, Ikeda Y. Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura. Role in production of anti-platelet autoantibody. J Clin Invest 1998; 102:1393–1402.
25. Kuwana M, Kaburaki J, Kitasato H et al. Immunodominant epitopes on glycoprotein IIb-IIIa recognized by autoreactive T cells in patients with immune thrombocytopenic purpura. Blood 2001;98:130–139.
26. Olsson B, Andersson PO, Jernås M et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003;9:1123–1124.
27. Yu J, Heck S, Patel V et al. Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood 2008;112:1325–1328.
28. Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284: 143–147.
29. Jorgensen C, Djouad F, Apparailly F et al. Engineering mesenchymal stem cells for immunotherapy. Gene Ther 2003;10:928–931.
30. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005;105: 1815–1822.
31. Prevosto C, Zancolli M, Canevali P et al. Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica 2007;92:881–888.
32. Ma L, Zhou Z, Zhang D et al. Immunosuppressive function of mesenchymal stem cells from human umbilical cord matrix in immune thrombocytopenia patients. Thromb Haemost 2012;107:937–950.
33. Xiao J, Zhang C, Zhang Y et al. Transplantation of adipose-derived mesenchymal stem cells into a murine model of passive chronic immune thrombocytopenia. Transfusion 2012;52: 2551–2558.
34. Lin R, Ma H, Ding Z et al. Bone marrow-derived mesenchymal stem cells favor the immunosuppressive T cells skewing in a Helicobacter pylori model of gastric cancer. Stem Cells Dev 2013;22:2836–2848.
35. Fang B, Mai L, Li N et al. Favorable response of chronic refractory immune thrombocytopenic purpura to mesenchymal stem cells. Stem Cells Dev 2012;21:497–502.
36. Vicencio JM, Galluzzi L, Tajeddine N et al. Senescence, apoptosis or autophagy? When a damaged cell must decide its path— A mini-review. Gerontology 2008;54:92–99.
37. Campisi J, d’Adda di Fagagna F. Cellular senescence: When bad things happen to good cells. Nat Rev Mol Cell Biol 2007;8:729–740.
38. Cagnol S, Chambard JC. ERK and cell death: Mechanisms of ERK-induced cell death —Apoptosis, autophagy and senescence. FEBS J 2010;277:2–21.
39. Martinou JC, Green DR. Breaking the mitochondrial barrier. Nat Rev Mol Cell Biol 2001; 2:63–67.
40. Ferri KF, Kroemer G. Mitochondria—The suicide organelles. BioEssays 2001;23:111–115.
41. Choi C, Benveniste EN. Fas ligand/Fas system in the brain: Regulator of immune and apoptotic responses. Brain Res Brain Res Rev 2004;44:65–81.
42. Zuckerman V, Wolyniec K, Sionov RV et al. Tumour suppression by p53: The importance of apoptosis and cellular senescence. J Pathol 2009;219:3–15.
43. Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature 2004;432:307– 315.
44. Vousden KH, Prives C. Blinded by the light: The growing complexity of p53. Cell 2009; 137:413–431.
45. Sherr CJ. G1 phase progression: Cycling on cue. Cell 1994;79:551–555.
46. Elmore S. Apoptosis: A review of programmed cell death. Toxicol Pathol 2007;35: 495–516.
47. Chipuk JE, Green DR. Dissecting p53-dependent apoptosis. Cell Death Differ 2006; 13:994–1002.
48. Meulmeester E, Jochemsen AG. P53: A guide to apoptosis. Curr Cancer Drug Targets 2008;8:87–97.
49. Shan NN, Hu Y, Hou M et al. Decreased Tim-3 and its correlation with Th1 cells in patients with immune thrombocytopenia. Thromb Res 2014;133:52–56.
50. Shao Q, Ning H, Lv J et al. Regulation of Th1/Th2 polarization by tissue inhibitor of metalloproteinase-3 via modulating dendritic cells. Blood 2012;119:4636–4644.
51. Li H, Zhao H, Xue F et al. Reduced expression of MIR409-3p in primary immune thrombocytopenia. Br J Haematol 2013;161: 128–135.
52. Donovan J, Abraham D, Norman J. Platelet-derived growth factor signaling in mesenchymal cells. Front Biosci (Landmark Ed) 2013;18:106–119.
53. Wang Y, Abu-Asab MS, Yu CR et al. Platelet-derived growth factor (PDGF)-C inhibits neuroretinal apoptosis in a murine model of focal retinal degeneration. Lab Invest 2014; 94:674–682.
54. Fingas CD, Bronk SF, Werneburg NW et al. Myofibroblast-derived PDGF-BB promotes hedgehog survival signaling in cholangiocarcinoma cells. Hepatology 2011;54:2076–2088.
55. Cheng J, Ye H, Liu Z et al. Platelet-derived growth factor-BB accelerates prostate cancer growth by promoting the proliferation of mesenchymal stem cells. J Cell Biochem 2013;114: 1510–1518.
56. Sotoca AM, Roelofs-Hendriks J, Boeren S et al. Comparative proteome approach demonstrates that platelet-derived growth factor C and D efficiently induce proliferation while maintaining multipotency of hMSCs. Exp Cell Res 2013;319:2649–2662.
57. Qiu P, Song W, Niu Z et al. Platelet-derived growth factor promotes the proliferation of human umbilical cord-derived mesenchymal stem cells. Cell Biochem Funct 2013;31:159–165.